ACW 6.67% 3.2¢ actinogen medical limited

Phase 2 clinical for Alzheimer's

  1. 19,998 Posts.
    lightbulb Created with Sketch. 1943
    This is an interesting stock with funds fully in place for the completion of Phase 2 Xanadu clinical trials for the safety and efficacy of ACW's Xanamem oral inhibitor drug that serves to block cortisol production in the brain. There has been scientific evidence linking cortisol production with the development of the Alzheimers disease. Much of this work that ACW has done stems from years of research and development at Edinburgh University.

    At mcap of just $29m [correction], IMO this is worth a small punt to participate in an Australian story that could have world groundbreaking success as the worldwide search continues with finding a cure for the Alzheimers disease. ACW success in receiving FDA approval to progress to Phase II IMO is already indeed a success in itself and the $29m mcap actually does not do any justice to its valuation.
    ------------------------------------------------------------------------------------------------------------------------------
    Data Winners Holdings: 3DP K2F* LNU BTH IXU CT1 SKT [all mcap<$100m]
    Other Potentials: GSW YOJ 4DS FFG DUB PIQ* TTT
 
watchlist Created with Sketch. Add ACW (ASX) to my watchlist
(20min delay)
Last
3.2¢
Change
0.002(6.67%)
Mkt cap ! $74.60M
Open High Low Value Volume
3.0¢ 3.2¢ 2.8¢ $52.54K 1.749M

Buyers (Bids)

No. Vol. Price($)
1 11059 3.0¢
 

Sellers (Offers)

Price($) Vol. No.
3.2¢ 154422 2
View Market Depth
Last trade - 16.10pm 29/03/2024 (20 minute delay) ?
Last
3.1¢
  Change
0.002 ( 6.90 %)
Open High Low Volume
2.9¢ 3.1¢ 2.9¢ 855992
Last updated 15.54pm 29/03/2024 ?
ACW (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.